{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:54:32Z","timestamp":1792054472734,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,5,23]],"date-time":"2006-05-23T00:00:00Z","timestamp":1148342400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,6,19]]},"DOI":"10.1038\/sj.bjc.6603170","type":"journal-article","created":{"date-parts":[[2006,5,23]],"date-time":"2006-05-23T17:26:24Z","timestamp":1148405184000},"page":"1765-1769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":400,"title":["AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL"],"prefix":"10.1038","volume":"94","author":[{"given":"E","family":"Weisberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mestan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Cowan-Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,5,23]]},"reference":[{"key":"BF6603170_CR1","doi-asserted-by":"publisher","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","volume":"65","author":"KJ Aichberger","year":"2005","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P (2005) Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukaemia: role of BCR-ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 65: 9436\u20139444","journal-title":"Cancer Res"},{"key":"BF6603170_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/306277a0","volume":"306","author":"CR Bartram","year":"1983","unstructured":"Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J (1983) Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306: 277\u2013280","journal-title":"Nature"},{"key":"BF6603170_CR3","first-page":"139","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6603170_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/325635a0","volume":"325","author":"LC Chan","year":"1987","unstructured":"Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, Powle R, Lawler SD, Groffen J, Foulkes JG, Greaves MF, Wiedemann LM (1987) A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 325: 635\u2013637","journal-title":"Nature"},{"key":"BF6603170_CR5","doi-asserted-by":"crossref","first-page":"204a","DOI":"10.1182\/blood.V106.11.204.204","volume":"106","author":"MWN Deininger","year":"2005","unstructured":"Deininger MWN, Bradeen H, Jia T, O'Hare T, Willis SG, Lee F, Druker BJ (2005) Comparison of imatinib, AMN107, and dasatinib in an accelerated cell-based mutagenesis screen. Blood 106: 204a","journal-title":"Blood"},{"key":"BF6603170_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561\u2013566","journal-title":"Nat Med"},{"key":"BF6603170_CR7","unstructured":"Fendrich G, Jacob SW, Klon AE, Manley PW (2006) Three-dimensional structure of human c-Abl kinase in complex with anti-tumor ligand, and use in drug discovery. US Patent Appl. Pub. 2006030017, April 9"},{"key":"BF6603170_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P (2006) PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 107: 752\u2013759","journal-title":"Blood"},{"key":"BF6603170_CR9","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","volume":"11","author":"M Golemovic","year":"2005","unstructured":"Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukaemia. Clin Cancer Res 11: 4941\u20134947","journal-title":"Clin Cancer Res"},{"key":"BF6603170_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876\u2013880","journal-title":"Science"},{"key":"BF6603170_CR11","doi-asserted-by":"crossref","first-page":"205a","DOI":"10.1182\/blood.V106.11.694.694","volume":"106","author":"JD Griffin","year":"2005","unstructured":"Griffin JD, Weisberg E (2005) Simultaneous administration of AMN107 and imatinib in the treatment of imatinib-sensitive and imatinib-resistant chronic myeloid leukaemia. Blood 106: 205a","journal-title":"Blood"},{"key":"BF6603170_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93\u201399","journal-title":"Cell"},{"key":"BF6603170_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med 349: 1423\u20131432","journal-title":"New Engl J Med"},{"key":"BF6603170_CR14","doi-asserted-by":"crossref","first-page":"314a","DOI":"10.1182\/blood.V106.11.314.314","volume":"106","author":"H Jorgensen","year":"2005","unstructured":"Jorgensen H, Allan E, Jordanides N, Hamilton A, Mountford J, Holyoake T (2005) AMN107 appears equipotent and may synergise with imatinib at the CML stem cell level through interaction with ABCG2. Blood 106: 314a","journal-title":"Blood"},{"key":"BF6603170_CR15","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Holzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottman OG (2006) AMN107, a novel, highly active, selective Bcr-Abl tyrosine kinase inhibitor in patients with Philadelphia Chromosome (Ph) positive chronic myelogenous leukaemia (CML) or acute lymphocytic leukaemia (ALL) who are resistant to imatinib mesylate therapy. New Engl J Med (in press)"},{"key":"BF6603170_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.1988.6.1.180","volume":"6","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Talpaz M (1988) Definition of the accelerated phase of chronic myelogenous leukaemia. J Clin Oncol 6: 180\u2013182","journal-title":"J Clin Oncol"},{"key":"BF6603170_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079\u20131082","journal-title":"Science"},{"key":"BF6603170_CR18","doi-asserted-by":"crossref","first-page":"251a","DOI":"10.1182\/blood.V104.11.4670.4670","volume":"104","author":"FX Mahon","year":"2004","unstructured":"Mahon FX, Lagarde V, Manley PW, Pasquet J-M, Turcq B, Reiffers J (2004) Generation of resistance cell lines to AMN107, a new inhibitor of Bcr-Abl, and its effects on cell lines sensitive and resistant to imatinib. Blood 104: 251a","journal-title":"Blood"},{"key":"BF6603170_CR19","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","volume":"14","author":"PW Manley","year":"2004","unstructured":"Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Furet P, Mestan J, Meyer T (2004) Urea-derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorg Med Chem Lett 14: 5793\u20135797","journal-title":"Bioorg Med Chem Lett"},{"key":"BF6603170_CR20","doi-asserted-by":"crossref","first-page":"940a","DOI":"10.1182\/blood.V106.11.3365.3365","volume":"106","author":"PW Manley","year":"2005","unstructured":"Manley PW, Cowan-Jacob SW, Fendrich G, Metan J (2005) Molecular interactions between the highly selective pan-Bcr-Abl inhibitor, AMN107, and the tyrosine kinase domain of Abl. Blood 106: 940a","journal-title":"Blood"},{"key":"BF6603170_CR21","first-page":"4236","volume":"62","author":"B Nagar","year":"2002","unstructured":"Nagar B, Bommann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62: 4236\u20134243","journal-title":"Cancer Res"},{"key":"BF6603170_CR22","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O'Hare","year":"2005","unstructured":"O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500\u20134505","journal-title":"Cancer Res"},{"key":"BF6603170_CR23","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100: 1965\u20131971","journal-title":"Blood"},{"key":"BF6603170_CR24","doi-asserted-by":"crossref","first-page":"148a","DOI":"10.1182\/blood.V106.11.148.148","volume":"106","author":"A Ray","year":"2005","unstructured":"Ray A, Cowan-Jacob S, Manley PW, Mestan J, Griffin JD (2005) Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 by a random mutagenesis study. Blood 106: 148a","journal-title":"Blood"},{"key":"BF6603170_CR25","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530\u20133539","journal-title":"Blood"},{"key":"BF6603170_CR26","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bommann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938\u20131942","journal-title":"Science"},{"key":"BF6603170_CR27","doi-asserted-by":"publisher","first-page":"318a","DOI":"10.1182\/blood-2004-09-3523","volume":"106","author":"NP Shah","year":"2005","unstructured":"Shah NP, Nicoll JM, Branford S, Hughes TP, Paquette RL, Talpaz M, Nicaise C, Huang F, Sawyers CL (2005) Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: rationale for combination tyrosine kinase inhibitor therapy. Blood 106: 318a","journal-title":"Blood"},{"key":"BF6603170_CR28","doi-asserted-by":"crossref","first-page":"52a","DOI":"10.1182\/blood.V106.11.166.166","volume":"106","author":"B Simonsson","year":"2005","unstructured":"Simonsson B (2005) Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP) treated with imatinib (IM): update from the IRIS Study. Blood 106: 52a","journal-title":"Blood"},{"key":"BF6603170_CR29","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","volume":"106","author":"EH Stover","year":"2005","unstructured":"Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, Fabbro D, Manley PW, Griffin JD, Gilliland DG (2005) The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106: 3206\u20133213","journal-title":"Blood"},{"key":"BF6603170_CR30","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","volume":"19","author":"N Von Bubnoff","year":"2005","unstructured":"Von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J (2005) The systemic mastocytosis-specific activating c-kit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukaemia 19: 1670\u20131671","journal-title":"Leukaemia"},{"key":"BF6603170_CR31","doi-asserted-by":"crossref","unstructured":"Von Bubnoff N, Sanger J, Manley PW, Mestan J, Peschel C, Duyster J (2006) Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor AMN107. Blood 107, (Epub ahead of print)","DOI":"10.1182\/blood-2005-12-010132"},{"key":"BF6603170_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129\u2013141","journal-title":"Cancer Cell"},{"key":"BF6603170_CR33","doi-asserted-by":"crossref","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino ACW, Cambareri A, Quinn S, Manley P, Hughes TP (2006) Oct-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not AMN107; reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 107 (in press)","DOI":"10.1182\/blood-2005-11-4687"}],"updated-by":[{"DOI":"10.1038\/s41416-019-0505-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6603170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603170","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:21:32Z","timestamp":1684412492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6603170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,23]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,6,19]]}},"alternative-id":["BF6603170"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6603170","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41416-019-0505-7","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,23]]},"assertion":[{"value":"15 February 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2011","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}